Our Featured Experts

Hyman B. Muss, MD
Dr. Muss on the Role of PARP Inhibitors in Breast Cancer
Hyman B. Muss, MD, professor of medicine, University of North Carolina-Chapel Hill School of Medicine, Breast Cancer Geriatric Oncology Program, director, geriatric oncology, UNC Lineberger Comprehensive Cancer Center, 2017 Giant of Cancer Care in Supportive/Palliative/Geriatric Care, discusses the addition of PARP inhibitors to the treatment landscape of breast cancer.
Mazyar Shadman, MD, MPH
Dr. Shadman on the Efficacy of Venetoclax in CLL
Mazyar Shadman, MD, MPH, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, University of Washington School of Medicine, and attending physician, Hematologic Malignancies, Seattle Cancer Care Alliance, discusses the efficacy of venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).
Oncology Specialists
Publication Bottom Border
Border Publication
x